GSK Announces Completion Of Pfizer's Exit Of Its Investment In ViiV Healthcare

11.7%: GSK and Shionogi completed a transaction replacing Pfizer's 11.7% economic interest in ViiV Healthcare with an investment by Shionogi, increasing Shionogi's economic stake. No financial terms or the new exact ownership percentage were disclosed; the deal consolidates Shionogi's position in ViiV and is a company-level structural change with limited broader market impact.

Analysis

11.7%: GSK and Shionogi completed a transaction replacing Pfizer's 11.7% economic interest in ViiV Healthcare with an investment by Shionogi, increasing Shionogi's economic stake. No financial terms or the new exact ownership percentage were disclosed; the deal consolidates Shionogi's position in ViiV and is a company-level structural change with limited broader market impact.